Mining town cut off by M23 rebels ‘has two weeks of supplies left'
Sources in Walikale, which was captured by the M23 on March 19, say the town is no longer safely accessible by road or air because of ongoing clashes between the army and rebels involving gunfire, drone strikes and explosions.
As a result, reserves of supplies and critical drugs including antibiotics, painkillers, and HIV drugs needed to treat hundreds of people seeking refuge in the town, are about to run out, they told The Telegraph.
'The last delivery we received of essential medicines and supplies was January 17,' said Marco Doneda, head of Medicines Sans Frontiers' programmes in North Kivu. 'If things do not change, we estimate that in two weeks we will run out of critical medications, including antibiotics.'
An MSF-supported hospital in the centre of the town is currently sheltering more than 700 civilians, who have fled their homes amid the near-constant gunfire and explosions that have rattled the area since the rebels launched their assault on the town.
'This is creating a situation that, from a point of view of hygiene, is not ideal at all, especially for a medical facility. It's impossible to get supplies, because there is no viable road to reach Walikale,' Mr Doneda said.
'We are also at risk because our hospital is not fortified or protected, it's in the middle of town and is totally exposed. On the first day of fighting, we came out of the facility to find gunfire had damaged our cars, and bullets had come through the gates,' he added.
Walikale sits atop large deposits of gold and tin, which is used as a protective coating for other metals and in industries including food packing and electronics.
Walikale is the Western-most town to fall to the M23 since they launched an offensive on the eastern DRC in January. The group has also captured the two major cities in the region, Goma and Bukavu.
More than 7,000 people have been killed and hundreds of thousands more displaced in the DRC since January in the latest escalation in conflict between the armed forces and the M23, which was formed in 2012 and has roots in the 1998 Rwandan genocide.
The group promised to withdraw from Walikale last week as a gesture of peace, but heavy fighting has continued in the area.
'These past days, the situation continues to deteriorate. The violence has severely impacted access to healthcare, as 80 per cent of the population has fled the city hearing artillery fire and fearing hostilities,' a spokesperson for the charity said.
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
17 hours ago
- Axios
RFK Jr.'s vaccine pullback stokes fears of lost medical breakthroughs
Health Secretary Robert F. Kennedy Jr.'s decision to cut federal funding for mRNA vaccine research is the latest in a series of moves that have the potential to crush future medical breakthroughs and accelerate a brain drain. Why it matters: America has historically led the world in scientific innovation — driving economic growth, strengthening national security, and attracting global talent. But scientists, including some who served in Trump's first administration, warn that lead is slipping away. The mRNA divestment "risks stalling progress in some of the most promising areas of modern medicine," Jerome Adams, surgeon general during the first Trump administration and now a professor at Purdue University, told Axios. "Walking away from this technology now would be like pulling funding from antibiotics after penicillin or from computers after the microchip. It's short-sighted and puts us at a disadvantage globally." State of play: Kennedy said last week that HHS's Biomedical Advanced Research and Development Authority would pull nearly $500 million worth of contracts with universities, drug companies and other labs working on new mRNA vaccines. No new mRNA-based projects will be launched as the administration shifts to "safer, broader vaccine platforms," he added. Scientists refute the implication that mRNA vaccines are unsafe. The technology that brought mRNA COVID vaccines in Trump's first term has been in development for decades. Large scientific trials and real-world data have shown that the vaccines are safe and effective — and capable of training the body's immune system to create antibodies to fight a host of afflictions. HHS, when asked for the research on which Kennedy based this decision, sent Axios a link to a citation collection put together by anti-COVID vaccine advocates, including Steven Hatfill, who promoted the use of the antimalarial drug hydroxychloroquine to treat the virus before vaccines were available despite reports of safety issues. Friction point: mRNA technology is what allowed the most common COVID vaccines to be deployed so quickly, and it's essential to responding to new viral pandemic threats, said Cynthia Leifer, a professor of immunology at Cornell University's College of Veterinary Medicine. "When we have a pandemic, we need to act quickly. We don't have time to wait several years or decades to do testing of older platforms the way they were normally done in years past," she said. "The newer technology could allow us to move so much faster to develop and have these vaccines rolled out to protect people when a pandemic is ongoing," Leifer added. Researchers are also studying how mRNA technology could treat or prevent cancer, HIV, and other chronic diseases — and the science so far is promising. Now, they're worried that progress could be lost. "If we stop now, we could delay or even miss the next generation of cures entirely," said Adams, the former surgeon general. Zoom out: Scientists say some of Kennedy's other changes are stifling innovation, too. Kennedy is working to implement massive staff cuts at HHS, reduce funding for research labs' overhead costs and end National Institutes of Health grants for a wide swath of projects. The cuts, along with the broader Trump administration's immigration restrictions, has already started to steer promising international scientific talent away from the country. Kennedy also is reportedly considering overhauling the U.S. Preventive Services Task Force, whose independent experts establish care and coverage guidelines to account for advances in medical treatments and new disease trends. Its past work included recommending beginning mammograms at 40, which has been credited with saving thousands of lives. The other side: HHS denies that its changes will stymie medical advances. "Those concerns are unfounded and not supported with facts," HHS Communications Director Andrew Nixon told Axios. Kennedy's decision to cut BARDA funding for mRNA work won't affect other government uses involving the technology, HHS said. The Centers for Disease Control and Prevention has endorsed mRNA COVID vaccines for most adults. Between the lines: An independent and bipartisan commission warned Congress in April that China has already pulled ahead of the U.S. in key life sciences areas. The U.S. can stay dominant, but it only has a few years to strengthen its position — and it needs to put significant resources into biotechnology resources, the commission's report said. Reality check: It's impossible to know whether breakthroughs actually won't happen as a result of these policy changes, or which advances we could miss out on. "That is a long-term impact that is hard to measure. What cure wasn't found? What question wasn't asked and investigated?" Richard Besser, CEO of the Robert Wood Johnson Foundation, said. mRNA therapy start-ups are also still raising private investment, which could keep research moving.
Chicago Tribune
20 hours ago
- Chicago Tribune
Volunteers, friends vow to carry on work of late Chicago LGBTQ+ activist: ‘We're her legacy'
Bobby Foster sobbed all day Monday, but there wasn't a doubt in his mind that he'd be back to work the following morning. He has to go on, he said, no matter what. 'If we have to do it with tears coming out our eyes, we gotta do it,' Foster, 57, said. Tuesday marked Foster's first volunteer shift at GroceryLand, the long-running Edgewater food pantry for HIV-positive people, without the pantry's steadfast linchpin, Lori Cannon. A fixture of LGBTQ+ activism in Chicago and the driving force behind GroceryLand, Cannon died at home Aug. 3 of heart failure, a close friend told the Tribune. She was 74. Less than 48 hours later, the doors of GroceryLand's 5543 N. Broadway brick-and-mortar stood open, as grieving volunteers returned to do what they had for years done side by side with Cannon: serve the community. They wouldn't have had it any other way, the volunteers said, as they vowed to carry on Cannon's legacy. 'This was her dream,' Foster said. 'This was her goal.' Born in Ravenswood and raised in West Rogers Park, Cannon established what would ultimately become GroceryLand 37 years ago amid the AIDS epidemic of the 1980s. Eleven years after AIDS was first reported in the United States, it was the leading cause of death for U.S. men ages 25 to 44. HIV disproportionally affects people in vulnerable populations that are often highly marginalized, stigmatized and criminalized, including the LGBTQ+ community, racial and ethnic minorities, women and girls, drug users and sex workers, according to the World Health Organization. 'I didn't understand what was happening,' Cannon told the Tribune in 2004 of the epidemic. 'But I knew I didn't like it. The horror, the heartbreak we experienced … and no one was paying attention.' Cannon turned to organizing, becoming an early volunteer for Chicago House, which provides a range of services for people and families affected by HIV, and helped launch the city's local chapter of the national AIDS Coalition to Unleash Power, according to the Chicago LGBT Hall of Fame. In 1988, Cannon co-founded Open Hand Chicago to deliver meals to people with AIDS. Six years later, Open Hand expanded to food pantries where clients could shop for their own free load of groceries, with the idea that they'd come away feeling more empowered in the process. GroceryLand was born. Over time, the operation evolved, being renamed Vital Bridges in 2001 and 10 years later, becoming an arm of Heartland Alliance Health, whose parent organization split apart last year amid financial turmoil. In February, Heartland Alliance Health itself was on the brink of closure before receiving a multimillion-dollar donation that saved the organization from shutting down. Still, through it all, GroceryLand remained, with Cannon at the helm. 'Lori Cannon was a true ally in Illinois from her organizing days to founding Open Hand Chicago — she led the way with chutzpah and humor,' Gov. JB Pritzker wrote in a statement to social media recently. That tenacity was palpable Tuesday, living on through the GroceryLand volunteers and clients Cannon leaves behind. 'We don't know what tomorrow's going to bring or how it's going to turn out,' Foster said as he wiped his eyes, his voice wavering. Foster initially came to the organization as a client when it was still known as Open Hand, after he contracted HIV at 20 years old. From Florida, he fell in love with Chicago from the moment he saw 'two guys walking down the street holding hands … and it seemed normal to them,' he said. Cannon gave Foster the 'guidance of the mother that I never had,' he said, sitting in GroceryLand's reception area as clients filtered in and out with canned goods, grains and vegetables in hand. All around, pride flags lined the pantry's walls while overhead, a doll resembling Cannon hung from angel wings, though the effigy had been part of the pantry's decor long before Cannon died as a standing homage to GroceryLand's 'guardian angel,' volunteers said. 'Will it be the same?' Foster said. 'Will we have the same support from the community? She knew so many people. She had so many connections. … Only time will tell. (But) the need is there.' Chicago artist David Lee Csicsko said he'll be a part of GroceryLand 'until I'm gone.' For more than 30 years, Csicsko has produced artwork for the pantry to liven the space and turn it into somewhere for not only 'nourishing your body but your mind and your soul and your heart,' he said. 'The constant thing was just making something that makes people smile.' That was important to Cannon, who exuded kindness and humor and knew every client that walked through the door by first name, Csicsko said. Today, GroceryLand, with the help of some 30 volunteers, serves a few hundred regular clients, volunteer Maria Mavraganes said. Mavraganes, 60, met Cannon when she was 16 years old, after she and her family, who had owned a restaurant in Lakeview for years, became involved in advocacy efforts early on in the AIDS epidemic, she said. When she retired four years ago, Mavraganes said she formally joined GroceryLand so she could volunteer 'for the community that gave so much to me and my family,' an opportunity she owed to Cannon. 'It's because of Lori and on Lori's behalf that we're all here.' she said. When client Frank Frasier took a bad fall last year and tore a tendon in his leg, it was Cannon who kept in touch and ensured he'd still receive his groceries, he said. A friend introduced Frasier, a longtime survivor of HIV, to GroceryLand seven years ago, and he's been a client, as well as a part-time volunteer, since. Cannon had this ability to 'make you feel like you're the most important person in the world,' said Frasier, who lived in Edgewater for 24 years but now lives in the suburbs. 'She never turned anybody away. Never. Whether it was a day's worth of food or a week's worth of food or whatever, even if they weren't a client, she didn't turn them away.' Frasier said it was always Cannon's hope that someday, GroceryLand wouldn't be necessary anymore. He referenced a 2016 article by the former hyperlocal news website DNAinfo Chicago, in which Cannon was quoted as saying, 'I hope to hang up the shingle on my front door that says, 'We're going fishing, we're closing our doors, the need is not there, it's been a pleasure serving you all.'' Frasier said that dream still stands. 'I don't want (her legacy) to be a dusty plaque someplace. I want it to keep living and breathing. … We're her legacy. The people here,' he paused, choking up, 'are her legacy. Clients, the people working.' Cannon's 'unwavering commitment to nourishing both bodies and spirits made Vital Bridges a lifeline for thousands,' Tamashiro continued, adding: 'We are profoundly grateful for (her) decades of leadership and love.' Tamashiro said Heartland Alliance Health is 'taking time to thoughtfully consider next steps for GroceryLand, ensuring that any decisions reflect the care, community and values Lori brought to her work every day.' Longtime Chicago performer Angelique Munro, who knew Cannon for 16 years, said the focus among Cannon's close network is 'the future of GroceryLand and the LGBTQ+ community' especially amid today's political climate. Heartland Alliance Health, which relies on federal funding for an estimated 20% to 30% of its annual budget, has been closely monitoring 'proposed changes to federal funding with concern,' Tamashiro said, though he added that the organization is 'on strong financial footing' and 'well-positioned' to continue delivering care. For the past 15 years, Munro, 55, has held an annual Thanksgiving food drive for GroceryLand to ensure that clients could take home a holiday meal. She plans to keep the tradition going this fall. Cannon was like a mother to Munro, whose own mother died in 2006, she said. Losing Cannon has 'shattered' her, but 'we just have to continue on,' she said, 'because that's what she would want. … It's all about honoring her and keeping her memory alive.' On that Tuesday afternoon, Derrick Fox walked towards GroceryLand with a black suitcase rolling behind him on the sidewalk. 'Are they servicing today?' the 63-year-old asked. Fox, of Englewood, met Cannon when GroceryLand opened and is 'living witness to what (the pantry) has done for us by way of Lori,' he said. 'I'm a longtime survivor,' he said. 'And I'm a longtime survivor because of her.'
Yahoo
a day ago
- Yahoo
Gilead's Yeztugo sales 'ahead of expectations' following launch
After Gilead Sciences was given the green light for Yeztugo (lenacapavir) in the US and Europe, CCO Johanna Mercier said it is 'well ahead of expectations' in a Q2 investor call. The twice-yearly pre-exposure prophylaxis (PrEP) therapy has made headlines for its capacity to prevent 100% of HIV cases in a trial involving South African and Ugandan women – resulting in the jab's approval in June. While Gilead did not reveal how much the flagship drug has made for the company thus far, Mercier noted that unaided awareness on Yeztugo was 'at about 72%,' which is 'more than double that you'd see in industry at launch'. Looking forward, GlobalData, parent company of Pharmaceutical Technology, has forecasted that the star HIV drug will bring in just under $5bn in 2031, making it one of the company's most lucrative assets. However, some analysts had concerns about the drug's future uptake following the Supreme Court's ruling to allow Robert F. Kennedy Jr. (RFK Jr.) free rein over the US Preventive Services Task Force's (USPSTF) staffing and decision-making. Though the USPSTF currently recommends the use of Yeztugo as a preventive therapy for HIV, analysts feared that the division's restructure or complete overhaul could impact guidelines around the PrEP's usage, though Mercier believes that Gilead could 'work through it' by collaborating closely with its payers if this were to occur. The World Health Organisation (WHO) also recently announced new guidelines, which shift the agency's focus to preventive treatments, while prioritising the lowering of barriers to patient care for HIV management. Gilead has pledged to allow affordable Yeztugo in low-and middle-income countries after UNAIDS' executive director, Winnie Byanyima, called upon Gilead to allow for the immediate production of Yeztugo generics, as the drug's $40k US price tag could leave many in lower-income countries unable to afford treatment. HIV portfolio drives Gilead's overall growth On top of the early-stage success enjoyed by Yeztugo, Gilead has reported positive results for its HIV portfolio as a whole, with sales in this indication totalling $4.15bn this quarter. Blockbuster antiretroviral Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) also had 'one of its best quarters ever,' with sales jumping 9% to $3.5bn – constituting nearly half of the pharma's overall profits in the second quarter. Though the drug's patent is set to expire in October 2027, GlobalData's infectious disease analyst Anaelle Tannen noted that no HIV therapy is likely to be superior to Biktarvy in terms of commercial success. This is supported by GlobalData's forecast of a sales drop for Biktarvy's main competitor Dovato (dolutegravir and lamivudine), produced by ViiV Healthcare, which GlobalData forecasts will drop from $3.4bn in 2027 to $1.6bn in 2031, in part due to patents likely being made available in 2031. Though the HIV market is highly lucrative, with GlobalData predicting the HIV market will surpass $32bn across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan). There are more than 40 drugs now approved for use in the indication, meaning pharma companies will have to differentiate themselves substantially to get a slice of this crowded market. One way companies are trying to differentiate is through the development of an HIV vaccine. While none have yet shown great promise, with two trials by Scripps Research, IAVI and additional collaborators across the US and Africa showing proof of concept at Phase I. "Gilead's Yeztugo sales 'ahead of expectations' following launch" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
